These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22402945)

  • 1. Murine models of diabetic nephropathy.
    Peters V; Schmitt CP
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):191-3. PubMed ID: 22402945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into the genetics of diabetic nephropathy through the study of mice.
    Breyer MD; Qi Z; Tchekneva EE; Harris RC
    Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):82-6. PubMed ID: 18090675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of diabetic nephropathy: lessons from mice.
    Breyer MD; Tchekneva E; Qi Z; Takahashi T; Fogo AB; Zhao HJ; Harris RC
    Semin Nephrol; 2007 Mar; 27(2):237-47. PubMed ID: 17418691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
    Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
    Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model for diabetic nephropathy: advantages of the inducible cAMP early repressor transgenic mouse over the streptozotocin-induced diabetic mouse.
    Inada A; Kanamori H; Arai H; Akashi T; Araki M; Weir GC; Fukatsu A
    J Cell Physiol; 2008 May; 215(2):383-91. PubMed ID: 18270980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy.
    Suganami T; Mukoyama M; Mori K; Yokoi H; Koshikawa M; Sawai K; Hidaka S; Ebihara K; Tanaka T; Sugawara A; Kawachi H; Vinson C; Ogawa Y; Nakao K
    FASEB J; 2005 Jan; 19(1):127-9. PubMed ID: 15496495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse models of diabetic nephropathy.
    Brosius FC; Alpers CE; Bottinger EP; Breyer MD; Coffman TM; Gurley SB; Harris RC; Kakoki M; Kretzler M; Leiter EH; Levi M; McIndoe RA; Sharma K; Smithies O; Susztak K; Takahashi N; Takahashi T;
    J Am Soc Nephrol; 2009 Dec; 20(12):2503-12. PubMed ID: 19729434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A sensitized screen of N-ethyl-N-nitrosourea-mutagenized mice identifies dominant mutants predisposed to diabetic nephropathy.
    Tchekneva EE; Rinchik EM; Polosukhina D; Davis LS; Kadkina V; Mohamed Y; Dunn SR; Sharma K; Qi Z; Fogo AB; Breyer MD
    J Am Soc Nephrol; 2007 Jan; 18(1):103-12. PubMed ID: 17151334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressions of chronic glomerular injuries and TGF-beta 1 production by HGF in attenuation of murine diabetic nephropathy.
    Mizuno S; Nakamura T
    Am J Physiol Renal Physiol; 2004 Jan; 286(1):F134-43. PubMed ID: 14519594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic kidney disease in the db/db mouse.
    Sharma K; McCue P; Dunn SR
    Am J Physiol Renal Physiol; 2003 Jun; 284(6):F1138-44. PubMed ID: 12736165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of an adenoviral vector encoding soluble transforming growth factor-beta type II receptor to the treatment of diabetic nephropathy in mice.
    Kondo T; Takemura G; Kosai K; Ohno T; Takahashi T; Esaki M; Goto K; Maruyama R; Murata I; Minatoguchi S; Fujiwara T; Fujiwara H
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1288-93. PubMed ID: 18505441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic nephropathy: leveraging mouse genetics.
    Breyer MD; Qi Z; Tchekneva E
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):227-32. PubMed ID: 16609287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery for diabetic nephropathy: trying the leap from mouse to man.
    Breyer MD
    Semin Nephrol; 2012 Sep; 32(5):445-51. PubMed ID: 23062985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice.
    Spencer MW; Mühlfeld AS; Segerer S; Hudkins KL; Kirk E; LeBoeuf RC; Alpers CE
    Am J Nephrol; 2004; 24(1):20-31. PubMed ID: 14671436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.
    Yamamoto Y; Kato I; Doi T; Yonekura H; Ohashi S; Takeuchi M; Watanabe T; Yamagishi S; Sakurai S; Takasawa S; Okamoto H; Yamamoto H
    J Clin Invest; 2001 Jul; 108(2):261-8. PubMed ID: 11457879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
    Inagi R; Nangaku M; Miyata T
    Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of diabetic nephropathy in CaM kinase IIalpha (Thr286Asp) transgenic mice.
    Suzuki H; Kato I; Usui I; Takasaki I; Tabuchi Y; Oya T; Tsuneyama K; Kawaguchi H; Hiraga K; Takasawa S; Okamoto H; Tobe K; Sasahara M
    Biochem Biophys Res Commun; 2009 Jan; 379(1):38-42. PubMed ID: 19070598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse Models for Studying Diabetic Nephropathy.
    Chow BSM; Allen TJ
    Curr Protoc Mouse Biol; 2015 Jun; 5(2):85-94. PubMed ID: 26069079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis in diabetic nephropathy.
    Zent R; Pozzi A
    Semin Nephrol; 2007 Mar; 27(2):161-71. PubMed ID: 17418685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.